Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis (DAISY)
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this multinational, randomized, placebo-controlled, and double blind study is to evaluate the safety and efficacy of subcutaneous (SC) anifrolumab in adult patients with systemic sclerosis (SSc), who may be taking one or a combination of protocol specified standard therapies. Following 52-weeks of double-blind, placebo-controlled treatment, a 52-week open-label treatment period is included to assess long-term safety in Systemic Sclerosis (SSc).
Closed for Enrollment
-
A Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Jacksonville, Fla.
The purpose of this study is to assess the safety of mesenchymal stem cells in patients with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorders (CTD).
-
A Phase II, Open-label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Efficacy of 8 mg/kg OR 4 mg/kg Intravenous Tocilizumab in Patients with Moderate-to-Severe COVID-19 Pneumonia (CA42481)
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is assess the pharmacodynamics, pharmacokinetics, safety and effectiveness of two different doses of Tocilizumab (TCZ) in combination with Standard of Care (SOC) in hospitalized adult patients with moderate-to-severe COVID-19 pneumonia.
-
A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to find out whether BI 685509 helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems.
-
Biospecimen Repository for Multi-omic Based Artificial Intelligence Approaches to Predict Response to Adalimumab (Humira) in Patients with Rheumatoid Arthritis (Almond II)
Jacksonville, Fla.
The purpose of this study is to collect clinical and biological measures to develop an Artificial Intelligence based algorithm and clinical decision support tool to predict the 12-week response to adalimumab, a tumor necrosis factor receptor antagonist in adults with a clinical diagnosis of rheumatoid arthritis.
-
The Mayo Clinic Early Arthritis Cohort Study
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to establish a cohort of clinical and biological samples of patients with early rheumatoid arthritis or arthritis like undifferentiated inflammatory arthritis in order to address multiple critical barriers that exist to improved outcomes for patients with RA and other chronic inflammatory arthritides, including: (1) gaps in understanding disease mechanisms; (2) the lack of highly useful diagnostic and prognostic tools; and (3) the unavailability of personalized, targeted therapies for patients with early inflammatory arthritis.
.